Novacyt Stock

Novacyt EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of Novacyt (ALNOV.PA) as of Jul 20, 2026 is -1.69. In the previous year, EV/EBIT (Enterprise Value to EBIT) was -1.77 — a change of -4.91% (higher).

EV/EBIT

-1.69

YoY

-4.91%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Novacyt is 2026 -1.69 . EV/EBIT (Enterprise Value to EBIT) of Novacyt was 2025 -1.77 . It decreases by -4.91% higher compared to the previous year.

The Novacyt EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PRICE-TO-EBIT
Date
PRICE-TO-EBIT
Jan 1, 2018
-0.15 base
Jan 1, 2019
-0.06 base
Jan 1, 2020
0.03 base
Jan 1, 2021
2.11 base
Jan 1, 2022
-0.05 base
Jan 1, 2023
-0.03 base
Jan 1, 2024
-0.02 base
Jan 1, 2025 (e)
0.11 base
YEARPRICE-TO-EBIT
2025 est 0.11
2024 -0.02
2023 -0.03
2022 -0.05
2021 2.11
2020 0.03
2019 -0.06
2018 -0.15
2017 -0.08
2016 -0.03
2015 -0.05
2014 -0.05
2013 -0.19
2012 -0.30
2011 -
2010 -
2009 -
2008 -
Access this data via the Eulerpool API

Novacyt Valuation

Details

Historical Valuation Multiples

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Novacyt's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Novacyt's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Novacyt's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Novacyt grows earnings faster than its peers.

Novacyt Stock analysis

What does Novacyt do? Novacyt SA is a leading biotechnology company specializing in the development and marketing of diagnostic products and technologies. The company was founded in 2006 and has experienced impressive growth since then. Its headquarters are located in Paris. Novacyt's business model revolves around the development and marketing of diagnostic products and technologies, particularly molecular diagnostic kits and reagents used for identification and quantification of microorganisms, viruses, and genetic differences. These products are commonly used in medical research, clinical diagnostics, and environmental analysis. Novacyt is divided into several divisions, each offering different products and services. Its diagnostic business specializes in the research, development, and marketing of molecular diagnostic kits, including the Primerdesign Kits specifically designed for COVID-19 identification. The company also provides laboratory and service offerings, such as DNA sequencing, qPCR analysis, sample preparation, and PCR disinfection. Additionally, Novacyt offers various diagnostic tests capable of detecting genetic differences and mutations. Its PathFlow division focuses on improving the process from diagnosis to therapy and follow-up, particularly for oncology patients. In response to the COVID-19 pandemic, Novacyt quickly launched a PCR test kit for COVID-19, which has been approved in numerous countries worldwide. Novacyt has successfully established itself as a key player in the fight against the pandemic. In summary, Novacyt SA is a leading biotechnology company specializing in the development and marketing of diagnostic products and technologies. Through its divisions, the company ensures the optimal utilization of molecular diagnostic tests. Novacyt has become an important player in the fight against the pandemic through its rapid response and development of molecular diagnostic kits for COVID-19, establishing itself as a reliable and innovative partner for medical research and clinical diagnostics. Novacyt is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Novacyt stock

EV/EBIT (Enterprise Value to EBIT) of Novacyt is -1.69 in 2026.

Access this data via the Eulerpool API

Valuation — Novacyt

All Key Metrics — Novacyt